Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol

被引:4
作者
Goldsmith, Petra M. [1 ,2 ]
Bottomley, Matthew J. [3 ]
Okechukwu, Okidi [4 ]
Ross, Victoria C. [5 ]
Ghita, Ryan [5 ]
Wandless, David [6 ]
Falconer, Stuart J. [7 ]
Papachristos, Stavros [4 ]
Nash, Philip [8 ]
Androshchuk, Vitaliy [3 ]
Clancy, Marc [7 ,9 ]
机构
[1] Royal Liverpool Univ Hosp NHS Trust, Renal Transplant Unit, Liverpool, Merseyside, England
[2] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England
[3] Oxford Univ Hosp NHS Fdn Trust, Dept Nephrol, Oxford, England
[4] Cent Manchester Univ Hosp NHS Fdn Trust, Dept Transplantat, Manchester, Lancs, England
[5] NHS Greater Glasgow & Clyde, Dept Transplantat, Glasgow, Lanark, Scotland
[6] NHS Grampian, Dept Nephrol, Aberdeen, Scotland
[7] NHS Lothian, Dept Transplantat, Edinburgh, Midlothian, Scotland
[8] Kings Coll Hosp NHS Fdn Trust, Dept Nephrol, London, England
[9] Univ Glasgow, Sch Med Dent & Surg, Glasgow, Lanark, Scotland
来源
BMJ OPEN | 2017年 / 7卷 / 07期
关键词
SOLID-ORGAN TRANSPLANTATION; CALCINEURIN INHIBITORS; RISK-FACTOR; PHARMACOKINETICS; RECIPIENTS; IMMUNOSUPPRESSION; PHARMACODYNAMICS; CYCLOSPORINE; NONADHERENCE; CLEARANCE;
D O I
10.1136/bmjopen-2017-016144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction High intrapatient variability (IPV) in tacrolimus trough levels has been shown to be associated with higher rates of renal transplant failure. There is no consensus on what level of IPV constitutes a risk of graft loss. The establishment of such a threshold could help to guide clinicians in identifying at-risk patients to receive targeted interventions to improve IPV and thus outcomes. Methods and analysis A multicentre Transplant Audit Collaborative has been established to conduct a retrospective study examining tacrolimus IPV and renal transplant outcomes. Patients in receipt of a renal transplant at participating centres between 2009 and 2014 and fulfilling the inclusion criteria will be included in the study. The aim is to recruit a minimum of 1600 patients with follow-up spanning at least 2 years in order to determine a threshold IPV above which a renal transplant recipient would be considered at increased risk of graft loss. The study also aims to determine any national or regional trends in IPV and any demographic associations. Ethics and dissemination Consent will not be sought from patients whose data are used in this study as no additional procedures or information will be required from participants beyond that which would normally take place as part of clinical care. The study will be registered locally in each participating centre in line with local research and development protocols. It is anticipated that the results of this audit will be disseminated locally, in participating NHS Trusts, through national and international meetings and publications in peer-reviewed journals.
引用
收藏
页数:4
相关论文
共 19 条
[1]   Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients [J].
Antignac, Marie ;
Barrou, Benoit ;
Farinotti, Robert ;
Lechat, Philippe ;
Urien, Saik .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (06) :750-757
[2]   High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation [J].
Borra, Lennaert C. P. ;
Roodnat, Joke I. ;
Kal, Judith A. ;
Mathot, Ron A. A. ;
Weimar, Willem ;
van Gelder, Teun .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (08) :2757-2763
[3]   New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation [J].
de Jonge, Hylke ;
Naesens, Maarten ;
Kuypers, Dirk R. J. .
THERAPEUTIC DRUG MONITORING, 2009, 31 (04) :416-435
[4]   Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation [J].
Dew, Mary Amanda ;
DiMartini, Andrea F. ;
Dabbs, Annette De Vito ;
Myaskovsky, Larissa ;
Steel, Jennifer ;
Unruh, Mark ;
Switzer, Galen E. ;
Zomak, Rachelle ;
Kormos, Robert L. ;
Greenhouse, Joel B. .
TRANSPLANTATION, 2007, 83 (07) :858-873
[5]   Reduced exposure to calcineurin inhibitors in renal transplantation [J].
Ekberg, Henrik ;
Tedesco-Silva, Helio ;
Demirbas, Alper ;
Vitko, Stefan ;
Nashan, Bjorn ;
Guerkan, Alp ;
Margreiter, Raimund ;
Hugo, Christian ;
Grinyo, Josep M. ;
Frei, Ulrich ;
Vanrenterghem, Yves ;
Daloze, Pierre ;
Halloran, Philip F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (25) :2562-2575
[6]   A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients [J].
Elens, Laure ;
Bouamar, Rachida ;
Hesselink, Dennis A. ;
Haufroid, Vincent ;
van der Heiden, Ilse P. ;
van Gelder, Teun ;
van Schaik, Ron H. N. .
CLINICAL CHEMISTRY, 2011, 57 (11) :1574-1583
[7]   The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? [J].
Hesselink, DA ;
van Gelder, T ;
van Schaik, RHN .
PHARMACOGENOMICS, 2005, 6 (04) :323-337
[8]  
Hong JC, 2000, SEMIN NEPHROL, V20, P108
[9]   Monitoring Nonadherence and Acute Rejection With Variation in Blood Immunosuppressant Levels in Pediatric Renal Transplantation [J].
Hsiau, Margaret ;
Fernandez, Hilda E. ;
Gjertson, David ;
Ettenger, Robert B. ;
Tsai, Eileen W. .
TRANSPLANTATION, 2011, 92 (08) :918-922
[10]   CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance [J].
Pashaee, Nilufar ;
Bouamar, Rachida ;
Hesselink, Dennis A. ;
Roodnat, Joke I. ;
van Schaik, Ron H. N. ;
Weimar, Willem ;
van Gelder, Teun .
THERAPEUTIC DRUG MONITORING, 2011, 33 (03) :369-371